Show simple item record

dc.contributor.authorHalle, Mari Kyllesøen_US
dc.contributor.authorTangen, Ingvild Løbergen_US
dc.contributor.authorBerg, Hege Fredriksenen_US
dc.contributor.authorHoivik, Erling Aen_US
dc.contributor.authorMauland, Karen Klepslanden_US
dc.contributor.authorKusonmano, Kanthidaen_US
dc.contributor.authorBerg, Annaen_US
dc.contributor.authorHurtado, Antonien_US
dc.contributor.authorKalland, Karl-Henningen_US
dc.contributor.authorØyan, Anne Margreteen_US
dc.contributor.authorStefansson, Ingunnen_US
dc.contributor.authorVintermyr, Olav Karstenen_US
dc.contributor.authorWerner, Henrica Maria Johannaen_US
dc.contributor.authorHaldorsen, Ingfrid S.en_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorSalvesen, Helga Birgitteen_US
dc.contributor.authorKrakstad, Camillaen_US
dc.description.abstractBackground: Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2) receptor in breast and gastric cancers, the potential of HER2 as a therapeutic target in other cancers has been less studied, including endometrial cancer. We investigated expression levels of HER2 (ERBB2) in a large cohort of endometrial cancer lesions, also including complex atypical hyperplasia and metastatic lesions. Methods: 67 precursor lesions, 790 primary endometrial cancers and 383 metastatic lesions were investigated for HER2 expression in relation to clinicopathologic features and outcome. Protein levels were assessed by immunohistochemistry (using the HercepTest and staining index (SI) criteria), mRNA levels by microarrays and amplification status by chromogenic in situ hybridisation. Results: High HER2 protein levels were significantly associated with features of aggressive disease and increased mRNA ERBB2 levels. HER2 expression defined by the SI proved to be a better predictor of survival compared with the HercepTest. A discordant HER2 expression pattern between paired primary and metastatic lesions was detected, revealing substantial reduction in HER2 expression from primary to metastatic disease. Conclusions: Loss of HER2 expression is common in metastatic endometrial cancer lesions and assessment of HER2 levels in the metastatic lesions may be important to define the potential benefit of anti-HER2 treatments in endometrial cancer patients.en_US
dc.publisherNature Publishing Groupeng
dc.relation.ispartof<a href="" target="blank"> Molecular alterations suggesting new treatment strategies in uterine carcinomas</a>
dc.rightsAttribution-NonCommercial-Share Alike CC BY-NC-SAeng
dc.subjectHER2 testingeng
dc.subjectendometrial carcinomaeng
dc.subjectprognostic biomarkerseng
dc.subjectchromogenic in situ hybridisationeng
dc.subjectmetastatic biopsieseng
dc.subjectantibody-drugs conjugateeng
dc.titleHER2 expression patterns in paired primary and metastatic endometrial cancer lesionsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 Cancer Research UK.
dc.source.journalBritish Journal of Cancer

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-Share Alike CC BY-NC-SA
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-Share Alike CC BY-NC-SA